PA8555401A1 - Derivados de quinolina - Google Patents

Derivados de quinolina

Info

Publication number
PA8555401A1
PA8555401A1 PA20028555401A PA8555401A PA8555401A1 PA 8555401 A1 PA8555401 A1 PA 8555401A1 PA 20028555401 A PA20028555401 A PA 20028555401A PA 8555401 A PA8555401 A PA 8555401A PA 8555401 A1 PA8555401 A1 PA 8555401A1
Authority
PA
Panama
Prior art keywords
quinoline derivatives
obesity
diabetes
esters
compounds
Prior art date
Application number
PA20028555401A
Other languages
English (en)
Inventor
Patrizio Mattei
Matthias Heinrich Nettekoven
Jean-Marc Plancher
Werner Mueller
Werner Neidhart
Philippe Pflieger
Michael G Klug
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8555401A1 publication Critical patent/PA8555401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPUESTOS DE FORMULA 1 ASI COMO LAS SALES Y ESTERES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE R1, R2, R3, A1 Y A2 TIENEN EL SIGNIFICADO DADO EN LA REIVINDICACION 1, SE PUEDEN USAR EN FORMA DE PREPARACIONES FARMACEUTICAS PARA EL TRATAMIENTO O PREVENCION DE ARTRITIS, ENFERMEDAD CARDIOVASCULARES, DIABETES, INSUFICIENCIA RENAL, TRASTORNOS ALIMENTARIOS Y OBESIDAD.
PA20028555401A 2001-09-28 2002-09-25 Derivados de quinolina PA8555401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01123496 2001-09-28

Publications (1)

Publication Number Publication Date
PA8555401A1 true PA8555401A1 (es) 2003-07-28

Family

ID=8178804

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028555401A PA8555401A1 (es) 2001-09-28 2002-09-25 Derivados de quinolina

Country Status (24)

Country Link
US (4) US6787558B2 (es)
EP (1) EP1432421A1 (es)
JP (1) JP4187652B2 (es)
KR (1) KR100605765B1 (es)
CN (1) CN1289087C (es)
AR (1) AR040626A1 (es)
AU (1) AU2002342735B2 (es)
BR (1) BR0212929A (es)
CA (1) CA2460865C (es)
GT (1) GT200200197A (es)
HK (1) HK1074176A1 (es)
HR (1) HRP20040272A2 (es)
HU (1) HUP0401481A2 (es)
IL (1) IL160750A0 (es)
MX (1) MXPA04002825A (es)
NO (1) NO20041235L (es)
NZ (1) NZ531517A (es)
PA (1) PA8555401A1 (es)
PE (1) PE20030603A1 (es)
PL (1) PL370414A1 (es)
RU (1) RU2300531C2 (es)
UY (1) UY27462A1 (es)
WO (1) WO2003028726A1 (es)
ZA (1) ZA200402359B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
WO2008142384A1 (en) * 2007-05-17 2008-11-27 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
MX2010008202A (es) * 2008-01-28 2010-12-06 Janssen Pharmaceutica Nv Derivados de tio-2-aminoquinolina 6-sustituida utiles como inhibidores de beta-secretasa (bace).
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
MX2015001500A (es) 2012-08-02 2015-04-08 Merck Sharp & Dohme Compuestos antidiabeticos triciclicos.
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9212144B2 (en) * 2014-01-10 2015-12-15 Northwestern University 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
US9663468B2 (en) 2014-01-10 2017-05-30 Northwestern University 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
ES2849560T3 (es) * 2016-05-04 2021-08-19 Genoscience Pharma Sas Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3917911A1 (en) * 2019-01-31 2021-12-08 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
WO2020231739A2 (en) * 2019-05-10 2020-11-19 Antidote Ip Holdings, Llc Compounds and methods for treating cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272824A (en) * 1962-12-06 1966-09-13 Norwich Pharma Co 4-amino-6, 7-di(lower) alkoxyquinolines
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
NZ330571A (en) 1996-10-01 1999-10-28 Kyowa Hakko Kogyo Kk Nitrogenous heterocyclic compounds that may contain sulphur or oxygen
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
US6199042B1 (en) * 1998-06-19 2001-03-06 L&H Applications Usa, Inc. Reading system
CN1170534C (zh) 1998-08-14 2004-10-13 霍夫曼-拉罗奇有限公司 含有脂酶抑制剂的药物组合物
TR200100472T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler
DE60026155T2 (de) 1999-09-30 2006-08-10 Neurogen Corp., Branford Einige alkylendiamin-substituierte heterocyclen
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists

Also Published As

Publication number Publication date
KR100605765B1 (ko) 2006-07-31
JP2005508923A (ja) 2005-04-07
JP4187652B2 (ja) 2008-11-26
HRP20040272A2 (en) 2004-08-31
UY27462A1 (es) 2003-04-30
WO2003028726A1 (en) 2003-04-10
NO20041235L (no) 2004-03-24
CA2460865A1 (en) 2003-04-10
IL160750A0 (en) 2004-08-31
PE20030603A1 (es) 2003-07-12
US20040259858A1 (en) 2004-12-23
HUP0401481A2 (hu) 2004-12-28
GT200200197A (es) 2003-06-19
EP1432421A1 (en) 2004-06-30
US20030158179A1 (en) 2003-08-21
KR20040039442A (ko) 2004-05-10
AR040626A1 (es) 2005-04-13
RU2004113207A (ru) 2005-05-27
US7166589B2 (en) 2007-01-23
US7064134B2 (en) 2006-06-20
US7012073B2 (en) 2006-03-14
US20060148794A1 (en) 2006-07-06
PL370414A1 (en) 2005-05-30
CN1289087C (zh) 2006-12-13
US20060063758A1 (en) 2006-03-23
BR0212929A (pt) 2004-10-13
RU2300531C2 (ru) 2007-06-10
ZA200402359B (en) 2005-05-03
AU2002342735B2 (en) 2005-09-22
CA2460865C (en) 2008-09-09
MXPA04002825A (es) 2004-07-02
CN1607951A (zh) 2005-04-20
NZ531517A (en) 2005-11-25
HK1074176A1 (en) 2005-11-04
US6787558B2 (en) 2004-09-07

Similar Documents

Publication Publication Date Title
PA8555401A1 (es) Derivados de quinolina
UY26926A1 (es) Derivados de la quinolina y quinazolina
UY27300A1 (es) Nuevos derivados de quinolina
UY27646A1 (es) Derivados de quinolina como antagonistas de npt
UY27097A1 (es) Derivados del indol
PA8534801A1 (es) Derivados de piperazina
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
BR0313747A (pt) Inibidores de transcriptase reversa de não-nucleosìdeo
DK1487444T3 (da) Anvendelse af pyridylamider som angiogeneseinhibitorer
ATE495155T1 (de) Heterocyclische inhibitoren von mek
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
UY27627A1 (es) Aza - arilpiperazinas
UY27018A1 (es) Derivados de la pirimidina
ECSP055844A (es) Nuevos compuestos triciclicos
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
UY27689A1 (es) Nuevos derivados de tiazol como antagonistas del receptor npy
UY27204A1 (es) Derivados de pieracina
UY27975A1 (es) Derivados de indolilo
PA8579301A1 (es) Derivados de tiazol
ATE429435T1 (de) 7h-pyrrolopyrimidinderivate
PA8576701A1 (es) Derivados de quinazolina
ITMI20060712A1 (it) Uso di aminaftone per la preparazione di un medicamento per il trattamento delle arteriopatie
DE60300683D1 (de) Prucaloprid-n-oxid